Top

Published in:

01-06-2021 | Bullous Pemphigoid | Clinical study

Dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Dipeptidyl peptidase-4 inhibitor (DPP4i)-induced bullous pemphigoid (BP) is most frequently reported in patients receiving vildagliptin, according to findings of a study published in Annals of Pharmacotherapy. …

Sun L, et al. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid. Annals of Pharmacotherapy : 9 Jun 2021. Available from: URL: http://doi.org/10.1177/10600280211022722

Title: Dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Bullous Pemphigoid
Sitagliptin
Vildagliptin
Linagliptin
Erythema
DPP-4-Inhibitor
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-97809-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Imatinib/nilotinib

Voriconazole

Fluoxetine

Multiple drugs

Atezolizumab

Trichlormethiazide/vasopressin